Review of tests for monitoring doxorubicin-induced cardiomyopathy.
about
A method for detection of doxorubicin-induced cardiotoxicity: Flow-mediated vasodilation of the brachial artery.Anticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts)Doxorubicin-induced cardiotoxicity in adult Indian patients on chemotherapy.Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations.Chemotherapy-induced cardiotoxicity.The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.The utility of cardiac stress testing for detection of cardiovascular disease in breast cancer survivors: a systematic review.Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomesBiomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.Anthracycline cardiotoxicity.Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patientsDoxorubicin induced heart failure: Phenotype and molecular mechanisms.Usefulness of myocardial performance index in multiple sclerosis mitoxantrone-induced cardiotoxicityRecent advances of cocktail chemotherapy by combination drug delivery systems.Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicityCardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trialA concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity.Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancerCatching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.Cancer cell spheroids for screening of chemotherapeutics and drug-delivery systems.Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma.Effect of cationic side-chains on intracellular delivery and cytotoxicity of pH sensitive polymer-doxorubicin nanocarriers.A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat.Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.Concomitant impairment of left ventricular systolic and diastolic function during doxorubicin therapy: a prospective radionuclide ventriculographic and echocardiographic study.Endothelins: a possible mechanism of cytostatics-induced cardiomyopathy.The motivation to reproject gated blood pool SPECT data as planar data.Utility of reprojected tomograms.Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
P2860
Q33807892-27BF311B-0A71-4265-BE91-658B87E95BE8Q33974943-7073337B-BD66-4B08-BB86-65B7966679B8Q33985488-05F97FC9-1619-4E44-B55B-04A2CD23FCAAQ34215077-2961A26E-F2CB-4B6A-82A7-B8526255B6D6Q34258080-4731122A-2C81-4087-9594-6C37DA4558C5Q34292469-DBDC49A3-1959-491F-A374-A43821E9AB90Q35043809-8FAD0F26-70D2-4702-AC85-11FA89848EE8Q35925266-E80C7F1D-84DD-4644-8F19-0A965A617C9FQ36095018-FDF51208-8B31-4FA3-B2A9-6E9D8F6D1641Q36624983-BDC5E420-F61B-49DE-ADF0-00609BCEAAF0Q36644505-44A64DBE-2113-4CA5-8467-9E6E5253D131Q36912561-B1872750-7F5D-4C6E-8766-E986BE725C3FQ36982852-762F0474-78E1-4125-A243-3868B2428413Q37206908-39F5386E-6891-449A-BEB8-F43940D30575Q37230118-25F69A06-DEB6-48EA-B489-46E0199D9D34Q37362703-8557D391-69DC-43B7-80AB-90EE5BE9BD9AQ37629634-8416FF89-4DEE-4CB5-A10D-74E77E1056E9Q37680490-A472C811-A71C-4B95-95E1-86A5F9A27046Q38222800-8CD1A9E2-1A08-4D44-8878-272122B51E89Q38495033-98CE74D0-FC3F-44F9-A798-D0A3A23CECC8Q39086982-EF7CB5EC-3E34-4894-95D5-32529E484DD6Q39264651-902BE422-7DB6-4757-8FC2-6779D1305906Q42726669-95BD52FC-A76C-478E-8CCB-61CE580CFCBBQ43683844-160FBEE7-BBAE-4981-BFBB-0363F07ADE87Q43910722-604865F9-1E9D-484D-AE67-A881856C4090Q44397250-2B3F341F-BA2C-4249-9AC9-0D17C9FD9AE5Q47722890-88175A2F-A3AB-4D88-B0CB-3632330A9914Q47909593-B6BD0F77-B35A-4F07-AF7D-A24DC0F281E2Q51064268-C350493E-9E0C-489F-B0E9-1BF6389F24BCQ51115713-5175F396-D188-4FC1-AE62-7F13FD485314
P2860
Review of tests for monitoring doxorubicin-induced cardiomyopathy.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Review of tests for monitoring doxorubicin-induced cardiomyopathy.
@en
type
label
Review of tests for monitoring doxorubicin-induced cardiomyopathy.
@en
prefLabel
Review of tests for monitoring doxorubicin-induced cardiomyopathy.
@en
P2093
P356
P1433
P1476
Review of tests for monitoring doxorubicin-induced cardiomyopathy.
@en
P2093
P304
P356
10.1159/000227621
P577
1996-11-01T00:00:00Z